exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088253 RNA Name: hsa-miR-367-3p RNA Type: miRNA Chromosome: chr4 Starnd: - Coordinate: Start Site(bp): 112647877 End Site(bp): 112647898 External Links: hsa-miR-367-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand FHL1 chrX 136146702 136211359 + LRP12 chr8 104489231 104589024 - RALY chr20 33993646 34108308 + THOC2 chrX 123600561 123733056 - ACTB chr7 5527148 5563784 - DCP2 chr5 112976702 113022195 + PKM chr15 72199029 72231822 - METTL7A chr12 50923472 50932510 + CCNF chr16 2429394 2458854 + ATP6V1A chr3 113747033 113812056 + SELENOT chr3 150602875 150630445 + HSPA4 chr5 133052013 133106449 + EML4 chr2 42169353 42332548 + VIM chr10 17228241 17237593 + TRIM13 chr13 49995888 50020481 + MRS2 chr6 24402908 24426194 + SCML2 chrX 18239313 18354688 - CGN chr1 151510510 151538692 + NCAPD3 chr11 134150119 134225454 - ADCY9 chr16 3953387 4116442 - ZNF451 chr6 57086844 57170305 + SAR1B chr5 134601149 134649271 - CALM2 chr2 47160083 47176921 - CTNNB1 chr3 41194741 41260096 + NEK4 chr3 52708444 52770946 - IGSF8 chr1 160091340 160098943 - SH3PXD2A chr10 103594027 103855543 - RAB9A chrX 13689128 13710504 + TUBA1C chr12 49188736 49274603 + TMED10 chr14 75131469 75176612 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001005 chr2 53921020 53978078 - hsa_circ_0001414 chr4 56277780 56284152 + hsa_circ_0000126 chr1 150997086 150999803 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005394.2 chr19 28435388 28727680 - AC008040.1 chr3 169939353 169966734 - AC074117.1 chr2 27356246 27367622 + AC130650.2 chr16 14150833 14153235 + DAPK1-IT1 chr9 87553454 87554459 + LINC01128 chr1 825138 859446 + MALAT1 chr11 65497688 65506516 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + PITPNA-AS1 chr17 1516931 1518096 + PURPL chr5 27217714 27496994 + SNHG5 chr6 85650491 85678932 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.